Sign In
Buy BIO
$304.83
-1.30 (-0.425%)
At Close: Jun 03, 2026
Tiziana Life Sciences to showcase breakthrough therapies at BIO-Europe 2024 Conference
04:31pm, Friday, 01'st Nov 2024
Tiziana Life Sciences Ltd (NASDAQ:TLSA) said it will participate in the upcoming BIO-Europe 2024 conference in Stockholm. The event will allow Tiziana to engage with industry leaders, potential collab
NEW YORK, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies
BIO Q3 Earnings and Revenues Surpass Estimates, Stock Up Aftermarket
09:46am, Thursday, 31'st Oct 2024
Bio-Rad witnesses growth across the Clinical Diagnostics segment in the third quarter, primarily driven by an increased demand for quality control and immunology products.
Bio-Rad's Management to Participate in Fireside Chat During UBS Global Healthcare Conference
09:00am, Thursday, 31'st Oct 2024
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that the company's Chie
Bio-Rad Laboratories, Inc. (BIO) Q3 2024 Earnings Call Transcript
08:22pm, Wednesday, 30'th Oct 2024
Bio-Rad Laboratories, Inc. (NYSE:BIO ) Q3 2024 Earnings Conference Call October 30, 2024 5:00 PM ET Company Participants Edward Chung - Vice President of Investor Relations Norman Schwartz - Chairman
Bio-Rad Laboratories (BIO) Beats Q3 Earnings and Revenue Estimates
06:51pm, Wednesday, 30'th Oct 2024
Bio-Rad Laboratories (BIO) came out with quarterly earnings of $2.01 per share, beating the Zacks Consensus Estimate of $1.28 per share. This compares to earnings of $2.33 per share a year ago.
Bio-Rad Laboratories beats quarterly profit estimates on strong sales in diagnostics unit
06:09pm, Wednesday, 30'th Oct 2024
Diagnostics firm Bio-Rad Laboratories posted third-quarter profit above Wall Street estimates on Wednesday, helped by a recovery in demand for analytical tools from its biotech clients and steady clin
BIO-TECHNE DECLARES DIVIDEND
06:30am, Wednesday, 30'th Oct 2024
MINNEAPOLIS , Oct. 30, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended Septemb
BIO-TECHNE RELEASES FIRST QUARTER FISCAL 2025 RESULTS
06:30am, Wednesday, 30'th Oct 2024
MINNEAPOLIS , Oct. 30, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today reported its financial results for the first quarter ended September 30, 2024. First Quarter FY2025 Highlights F
What to Expect From These 3 MedTech Stocks This Earnings Season
12:31pm, Tuesday, 29'th Oct 2024
Here is a sneak peek into how three MedTech companies, ZBH, BIO and TECH, are expected to fare in their upcoming quarterly results, slated to be released tomorrow.
Tonix Pharmaceuticals to Present at BIO-Europe® 2024
08:00am, Tuesday, 29'th Oct 2024
CHATHAM, N.J., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pi
HOLMDEL, N.J., Oct. 29, 2024 (GLOBE NEWSWIRE) -- BIO-key® International, Inc. (NASDAQ: BKYI), an innovative provider of workforce and customer identity and access management (IAM) solutions featuring
FibroBiologics to Present at the 2024 ThinkEquity Conference and BIO-Europe 2024
09:31am, Monday, 28'th Oct 2024
HOUSTON, Oct. 28, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the d
Analysts Estimate Bio-Rad Laboratories (BIO) to Report a Decline in Earnings: What to Look Out for
11:06am, Wednesday, 23'rd Oct 2024
Bio-Rad (BIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SEATTLE, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (NASDAQ: ATOS) (“Atossa” or the “Company”), today announced that Steven Quay, M.D., Ph.D., Chairman and Chief Executive Off
